Products - Eye conditions | Topic

Showing 15 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Tebentafusp for treating advanced uveal melanoma (TA1027)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 January 2025
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 December 2024
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 October 2024
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2024
Diabetic retinopathy: management and monitoring (NG242)
Product type:
Guidance
Programme:
NICE guideline
Published:
13 August 2024
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 April 2025
Teprotumumab for treating thyroid eye disease [ID6432]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ranibizumab port delivery system for treating diabetic macular oedema ID6137
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
NVK-002 for treating myopia in people 3 to 17 years TSID 11961
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Polyhexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Eye conditions Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 15 products

Tebentafusp for treating advanced uveal melanoma (TA1027)

Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)

Diabetic retinopathy: management and monitoring (NG242)

Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]

Teprotumumab for treating thyroid eye disease [ID6432]

Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

Ranibizumab port delivery system for treating diabetic macular oedema ID6137

Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

NVK-002 for treating myopia in people 3 to 17 years TSID 11961

Polyhexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

Eye conditions Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 15 products

Product type
1 selected

New and updated
1 selected